Stellar Biotech Inc (SBOTF) 0.6700 $SBOTF
Stellar Biotechnologies, Inc. (Nasdaq:SBOT) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Wed Nov 04, 9:00AM CST
What:
SBOT: 3.14 (unch), NDAQ: 65.07 (-0.08)
Stellar Biotechnologies Announces Approval of NASDAQ Uplisting
Marketwired - Tue Nov 03, 3:15PM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , today announced that the Company has received approval for its common shares to begin trading on The NASDAQ Capital Market ("Nasdaq" .
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Announces Results of Special Meeting of Shareholders
Marketwired - Thu Oct 29, 2:04PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , announces that a Special Meeting of Shareholders was held today, October 29, 2015 (the "Meeting" , at which a proposed change to the Company's Articles (bylaws) was approved.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies and Amaran Biotechnology Provide Update on Collaboration
Marketwired - Thu Oct 01, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , is pleased to provide an update on the Company's ongoing collaboration with privately-held Taiwan biopharmaceuticals manufacturer Amaran Biotechnology, Inc. ("Amaran" .
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
Marketwired - Fri Aug 28, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , today announced that, subject to regulatory approval, the Company will proceed with a consolidation of its issued and outstanding common shares (the "Shares" on the basis of one (1) post-consolidated common Share for every ten (10) pre-consolidated Shares (the "Reverse Split" .
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Reports Third Quarter 2015 Financial Results and Operational Highlights
Marketwired - Mon Aug 10, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapy markets, today announced its financial results for the third fiscal quarter ended June 30, 2015.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Signs Collaboration Agreement to Expand KLH Aquaculture Operations
Marketwired - Tue Jul 28, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), a leading provider of Keyhole Limpet Hemocyanin (KLH) protein, today announced that the Company has entered into a collaboration agreement with Ostiones Guerrero SA de CV ("Ostiones" (the "Agreement" to secure a unique strategic site in Baja California, Mexico for the development of an additional aquaculture locale and expansion of Stellar KLH(TM) production to meet the increasing needs of its customers.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Retains The Ruth Group to Advance Communications Objectives
Marketwired - Thu Jul 09, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), a leading provider of Keyhole Limpet Hemocyanin (KLH) protein, a crucial component for the development of many novel immunotherapies, today announced that it has retained New York City-based investor and public relations agency The Ruth Group as its strategic communications advisors.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies to Present at 5thAnnual LD Micro Invitational
Marketwired - Mon Jun 01, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that Stellar executives will present at the 5th Annual LD Micro Invitational Conference, being held June 1-3, 2015 at the Luxe Sunset Boulevard Hotel, Los Angeles, CA.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies to Present at 2015 Marcum MicroCap Conference
Marketwired - Wed May 27, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that Company executives will present at the 2015 Marcum MicroCap Conference, being held May 27-28, 2015 at the Grand Hyatt in New York City, NY.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies' Immunology 2015 Poster Available Online
Marketwired - Fri May 15, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that the Company's poster presentation at this week's IMMUNOLOGY 2015 conference, the Annual Meeting of the American Association of Immunologists (AAI), has been posted to the Company's website. http://tinyurl.com/n5hq43w.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Reports Second Quarter 2015 Financial Results
Marketwired - Mon May 11, 3:30PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, today announced its financial results for the second fiscal quarter and six months ended March 31, 2015.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Presents Poster at Immunology 2015 on the Immunogenicity of Different Forms and Preparations of KLH
Marketwired - Thu Apr 30, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of results from preclinical studies analyzing the immunogenicity of different forms and preparations of Keyhole Limpet Hemocyanin (KLH), and relating to the Company's work in developing methods to identify the appropriate functional properties of KLH for use in immunotherapy and immunodiagnostic applications.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship
Marketwired - Wed Apr 01, 1:00AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) and Neovacs S.A. ("Neovacs" (ALTERNEXT PARIS: ALNEV) today announced that the Companies have entered into an expanded supply agreement to meet Neovacs' requirements for Keyhole Limpet Hemocyanin (KLH), a primary component of Neovacs' proprietary Kinoid immunotherapy technology.
KLH.VN: 5.380 (-0.230)
First FDA Breakthrough Therapy Designation for KLH-Conjugate Immunotherapy Signals Key Step for Novel Carrier Molecule
Marketwired - Tue Mar 10, 4:32PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" is encouraged that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for a KLH-based immunotherapy compound in the treatment of adult patients with EGFRvIII-positive glioblastoma being developed by Celldex Therapeutics, Inc.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Reports First Quarter 2015 Financial Results
Marketwired - Mon Feb 09, 7:30AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, announced financial results for the first quarter period ended December 31, 2014.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies to Present at Biotech Showcase(TM) 2015 Conference
Marketwired - Thu Jan 08, 7:31AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that the Company's management team will present at the 7th Annual Biotech Showcase 2015 conference, being held at the Parc 55 Wyndham Hotel in San Francisco, CA, on Tuesday, January 13 at 2:30 p.m. PST.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Reports Year-End 2014 Financial Results
Marketwired - Thu Nov 13, 9:17AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, has reported preliminary financial results for the year ended August 31, 2014.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies and Araclon Biotech Sign Exclusive KLH Supply Agreement for Clinical Trials in Alzheimer's Active Immunotherapies
Marketwired - Tue Nov 11, 11:46AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) and Araclon Biotech SL ("Araclon" today announced that the companies have executed a definitive exclusive supply agreement to meet Araclon's Phase (II and III) clinical trial requirements for Keyhole Limpet Hemocyanin (KLH) used in Araclon's active immunotherapies against Alzheimer's disease.
KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies, Inc. (Nasdaq:SBOT) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Wed Nov 04, 9:00AM CST
What:
SBOT: 3.14 (unch), NDAQ: 65.07 (-0.08)
Stellar Biotechnologies Announces Approval of NASDAQ Uplisting
Marketwired - Tue Nov 03, 3:15PM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , today announced that the Company has received approval for its common shares to begin trading on The NASDAQ Capital Market ("Nasdaq" . KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Announces Results of Special Meeting of Shareholders
Marketwired - Thu Oct 29, 2:04PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , announces that a Special Meeting of Shareholders was held today, October 29, 2015 (the "Meeting" , at which a proposed change to the Company's Articles (bylaws) was approved. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies and Amaran Biotechnology Provide Update on Collaboration
Marketwired - Thu Oct 01, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , is pleased to provide an update on the Company's ongoing collaboration with privately-held Taiwan biopharmaceuticals manufacturer Amaran Biotechnology, Inc. ("Amaran" . KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
Marketwired - Fri Aug 28, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , today announced that, subject to regulatory approval, the Company will proceed with a consolidation of its issued and outstanding common shares (the "Shares" on the basis of one (1) post-consolidated common Share for every ten (10) pre-consolidated Shares (the "Reverse Split" . KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Reports Third Quarter 2015 Financial Results and Operational Highlights
Marketwired - Mon Aug 10, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapy markets, today announced its financial results for the third fiscal quarter ended June 30, 2015. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Signs Collaboration Agreement to Expand KLH Aquaculture Operations
Marketwired - Tue Jul 28, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), a leading provider of Keyhole Limpet Hemocyanin (KLH) protein, today announced that the Company has entered into a collaboration agreement with Ostiones Guerrero SA de CV ("Ostiones" (the "Agreement" to secure a unique strategic site in Baja California, Mexico for the development of an additional aquaculture locale and expansion of Stellar KLH(TM) production to meet the increasing needs of its customers. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Retains The Ruth Group to Advance Communications Objectives
Marketwired - Thu Jul 09, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), a leading provider of Keyhole Limpet Hemocyanin (KLH) protein, a crucial component for the development of many novel immunotherapies, today announced that it has retained New York City-based investor and public relations agency The Ruth Group as its strategic communications advisors. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies to Present at 5thAnnual LD Micro Invitational
Marketwired - Mon Jun 01, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that Stellar executives will present at the 5th Annual LD Micro Invitational Conference, being held June 1-3, 2015 at the Luxe Sunset Boulevard Hotel, Los Angeles, CA. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies to Present at 2015 Marcum MicroCap Conference
Marketwired - Wed May 27, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that Company executives will present at the 2015 Marcum MicroCap Conference, being held May 27-28, 2015 at the Grand Hyatt in New York City, NY. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies' Immunology 2015 Poster Available Online
Marketwired - Fri May 15, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that the Company's poster presentation at this week's IMMUNOLOGY 2015 conference, the Annual Meeting of the American Association of Immunologists (AAI), has been posted to the Company's website. http://tinyurl.com/n5hq43w. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Reports Second Quarter 2015 Financial Results
Marketwired - Mon May 11, 3:30PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, today announced its financial results for the second fiscal quarter and six months ended March 31, 2015. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Presents Poster at Immunology 2015 on the Immunogenicity of Different Forms and Preparations of KLH
Marketwired - Thu Apr 30, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of results from preclinical studies analyzing the immunogenicity of different forms and preparations of Keyhole Limpet Hemocyanin (KLH), and relating to the Company's work in developing methods to identify the appropriate functional properties of KLH for use in immunotherapy and immunodiagnostic applications. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship
Marketwired - Wed Apr 01, 1:00AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) and Neovacs S.A. ("Neovacs" (ALTERNEXT PARIS: ALNEV) today announced that the Companies have entered into an expanded supply agreement to meet Neovacs' requirements for Keyhole Limpet Hemocyanin (KLH), a primary component of Neovacs' proprietary Kinoid immunotherapy technology. KLH.VN: 5.380 (-0.230)
First FDA Breakthrough Therapy Designation for KLH-Conjugate Immunotherapy Signals Key Step for Novel Carrier Molecule
Marketwired - Tue Mar 10, 4:32PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" is encouraged that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for a KLH-based immunotherapy compound in the treatment of adult patients with EGFRvIII-positive glioblastoma being developed by Celldex Therapeutics, Inc. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Reports First Quarter 2015 Financial Results
Marketwired - Mon Feb 09, 7:30AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, announced financial results for the first quarter period ended December 31, 2014. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies to Present at Biotech Showcase(TM) 2015 Conference
Marketwired - Thu Jan 08, 7:31AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that the Company's management team will present at the 7th Annual Biotech Showcase 2015 conference, being held at the Parc 55 Wyndham Hotel in San Francisco, CA, on Tuesday, January 13 at 2:30 p.m. PST. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies Reports Year-End 2014 Financial Results
Marketwired - Thu Nov 13, 9:17AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, has reported preliminary financial results for the year ended August 31, 2014. KLH.VN: 5.380 (-0.230)
Stellar Biotechnologies and Araclon Biotech Sign Exclusive KLH Supply Agreement for Clinical Trials in Alzheimer's Active Immunotherapies
Marketwired - Tue Nov 11, 11:46AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company"
(OTCQB: SBOTF) (TSX VENTURE: KLH) and Araclon Biotech SL ("Araclon" today announced that the companies have executed a definitive exclusive supply agreement to meet Araclon's Phase (II and III) clinical trial requirements for Keyhole Limpet Hemocyanin (KLH) used in Araclon's active immunotherapies against Alzheimer's disease. KLH.VN: 5.380 (-0.230)
